Last --
Change Today 0.00 / 0.00%
Volume 0.0
4502 On Other Exchanges
Symbol
Exchange
4502 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Cuts 83 Jobs in Switzerland

Takeda announced that it will outsource 83 of its full-time jobs in the town Glattbrugg, northeastern Switzerland, abroad. Currently a total of 360 people work in Glattbrugg. Part of the global marketing unit at the company's site in Zurich will also be relocated to Takeda's national branches, as wells as part of the medical affairs unit will also be transferred to branches in other countries. The Swiss subsidiary Takeda Pharma AG will not be affected by the plans. Glattbrugg, however, will remain the company's European headquarters.

Takeda Pharmaceutical Company Limited Announces the Results of Phase 3 Trial of Trelagliptin Succinate (SYR-472) for the Treatment of Type 2 Diabetes Mellitus at the 50th EASD Annual Meeting

Takeda Pharmaceutical Company Limited announced the results of a phase 3 trial of trelagliptin succinate (general name, development code: SYR-472) for the treatment of Type 2 diabetes mellitus at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting, which is being held in Vienna, Austria from September 15-19, 2014. Trelagliptin succinate is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor. It controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, two incretin hormones that play an important role in blood glucose regulation. The inhibition of DPP-4 increases insulin secretion depending on blood glucose concentration, thereby controlling blood glucose levels. Takeda has submitted the New Drug Application to the Ministry of Health, Labour and Welfare for this compound in March 2014.

Takeda Pharmaceutical Company Limited Announces Reorganization to Propel Continued Growth; Announces Management Changes, Effective October 1, 2014

Takeda Pharmaceutical Company Limited announced plans to redesign its global organizational structure to realize its goal of becoming a more agile, best-in-class pharmaceutical company with both a patient and customer focus. The planned organizational changes are designed to allow Takeda to sharpen its strategy, to respond with greater agility to evolving market needs and capitalize on growth opportunities across the globe. This new organizational structure places a patient and customer centric mindset as top priority, while aiming to clearly define accountability and ownership, simplify organization, and allow the company to operate more efficiently and competitively. The company's new organizational structure will redefine all regional commercial divisions into five Regional Business Units and two Specialty Business Units. The five newly established Regional Business Units will be Japan Pharma, Emerging Markets, United States, Europe-Canada, and Japan Consumer Healthcare, while the two newly established Specialty Business Units will be Oncology and Vaccines. Additionally, the R&D organization will be realigned into four Therapeutic Area Units, namely Central Nervous System (CNS), Cardiovascular and Metabolic (CVM), Gastroenterology (GI) and Oncology. However, it is planned that the changes announced will be fully implemented by April, 1. The key features are Establishment of 5 Regional Business Units; Establishment of 2 Specialty Business Units; Establishment of 4 Therapeutic Area Units. In addition to the previously established and appointed positions of Chief Financial Officer (CFO), Global Human Resources Officer (GHRO), Chief Medical & Scientific Officer (CMSO), Global Manufacturing and Supply Officer (GMSO) and Global Quality Officer (GQO), Takeda will further recognize the following three newly established positions: Corporate Strategy Officer (CSO), Corporate Communications and Public Affairs Officer (CCPAO) and Global General Counsel (GGC). Anna Protopapas will step down as President of Millennium and Head of Global Licensing and Business Development and leave Takeda effective October 1, 2014. Appointed Gerard Greco, Ph.D. as Global Quality Officer, Thomas Wozniewski, Ph.D. as Global Manufacturing and Supply Officer, Tadataka Yamada, M.D. as Chief Medical & Scientific Officer, Giles Platford as President, Emerging Markets Business Unit, Douglas Cole as President, US Business Unit, Trevor Smith as President, EUCAN Business Unit, Masato Iwasaki, Ph.D. as President, Japan Pharma Business Unit, Rajeev Venkayya, M.D. as President, Global Vaccine Business Unit, Christophe Bianchi, M.D. as President, Global Oncology Business Unit, Haruhiko Hirate as Corporate Communications and Public Affairs Officer, Yoshihiro Nakagawa as Global General Counsel, David Osborne as Global Human Resources Officer, Francois-Xavier Roger as Chief Financial Officer, Shinji Honda as Corporate Strategy Officer. The above appointments are effective October 1, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥4,928.00 JPY +34.50

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.40 USD -0.19
Astellas Pharma Inc ¥1,596 JPY -4.50
Baxter International Inc $72.07 USD -0.47
Becton Dickinson and Co $112.75 USD -0.95
Bristol-Myers Squibb Co $51.67 USD +0.16
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 32.6x
Price/Sales 2.1x
Price/Book 1.5x
Price/Cash Flow 12.7x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.